Hyperuricemia and bone marrow transplantation

Contributions to Nephrology

Volumn 147, Issue , 2005, Pages 105-114

  Deliliers, Giorgio Lambertenghi ^a,b   Annaloro, Claudio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

BONE MARROW TRANSPLANTATION; HUMAN; HYPERURICEMIA; LESCH NYHAN SYNDROME; METABOLIC SYNDROME X; REVIEW;

BONE MARROW TRANSPLANTATION; CYCLOSPORINE; HUMANS; HYPERURICEMIA; LESCH-NYHAN SYNDROME; METABOLIC SYNDROME X;

EID: 16644372867     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (60)

1. Cannell PK, Herrmann RP: Urate metabolism during bone marrow transplantation. Bone Marrow Transplant 1992;10:337-339.
2. Andreoli SP, Clark JH, McGuire WA: Purine excretion during tumor lysis in children with acute lymphoblastic leukemia receiving allopurinol: Relationships to acute renal failure. J Pediatr 1986; 109:292-298.
3. Linck D, Basara N, Tran V, Vucinic V, Hermann S, Hoelzer D, Fauser AA: Peracute onset of severe tumor lysis syndrome immediately after 4 Gy fractionated TBI as part of reduced intensity preparative regimen in a patient with T-ALL with high tumor burden. Bone Marrow Transplant 2003;31: 935-937.
4. Loosveld OJL, Schouten HC, Gaillard CA: Acute tumor lysis syndrome in a patient with acute lymphoblastic leukaemia after a single dose of prednisolone. Br J Haematol 1991;77:122-123.
5. Zurcher RM, Bock HA, Thiel G: Hyperuricaemia in cyclosporin-treated patients: GFR-related effect. Nephrol Dial Transplant 1996;11:153-158.
6. Chevion S, Or R, Berry EM: The antioxidant status of patients subjected to total body irradiation. Biochem Mol Biol Int 1999;47:1019-1027.
7. Durken M, Agbenu J, Finckh B, Hubner C, Pichlmeier U, Zeller W, Winkler K, Zander A, Kohlschutter A: Deteriorating free radical-trapping capacity and antioxidant status in plasma during bone marrow transplantation. Bone Marrow Transplant 1995;15:757-762.
8. Durken M, Herrnring C, Finckh B, Nagel S, Nielsen P, Fischer R, Berger HM, Moison RM, Pichlmeier U, Kohlschutter B, Zander AR, Kohlschutter A: Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free Radic Biol Med 2000;15:28:887-894.
9. Many A, Hubel CA, Roberts JM: Hyperuricemia and xanthine oxidase in preeclampsia, revisited. J Obstet Gynecol 1996;174:288-291.
10. Ellis J, Wennerholm UB, Bengtsson A, Lilja H, Pettersson A, Sultan B, Wennergren M, Hagberg H: Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Acta Obstet Gynecol Scand 2001;80:602-608.
11. Belo L, Santos-Silva A, Caslake M, Cooney J, Pereira-Leite L, Quintanilha A, Rebelo I: Neutrophil activation and C-reactive protein concentration in preeclampsia. Hypertens Pregnancy 2003;22: 129-141.
12. Aronson D, Bartha P, Zinder O, Kerner A, Shitman E, Markiewicz W, Brook GJ, Levy Y: Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med 2004;21:39-44.
13. Giordano N, Santacroce C, Mattii G, Geraci S, Amendola A, Gennari C: Hyperuricemia and gout in thyroid endocrine disorders. Clin Exp Rheumatol 2001;19:661-665.
14. Yazar A, Doven O, Atis S, Gen R, Pata C, Yazar EE, Kanik A: Systolic pulmonary artery pressure and serum uric acid levels in patients with hyperthyroidism. Arch Med Res 2003;34:35-40.
15. Webb DE, Austin HA 3rd, Belldegrun A, Vaughan E, Linehan WM, Rosenberg SA: Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol 1988;30: 141-145.
16. Schomburg A, Kirchner H, Atzpodien J: Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: Evidence of a risk/benefit advantage of subcutaneous therapy. J Cancer Res Clin Oncol 1993;119:745-755.
17. Da Sliva B, Gapstur SM, Achenbach YH, Schuh TS, Kotlar TJ, Liu K, Lowe WL Jr: Lack of association between the -308 polymorphism of the tumor necrosis factor-alpha gene and the insulin resistance syndrome. J Investig Med 2000;48:236-244.
18. Ishii T, Hirose H, Saito I, Nishikai K, Maruyama H, Saruta T: Tumor necrosis factor alpha gene G-308A polymorphism, insulin resistance, and fasting plasma glucose in young, older, and diabetic Japanese men. Metabolism 2000;49:1616-1618.
19. Johansson JE, Soussi B, Bagge U, Ekman T: Disturbance of purine nucleotide metabolism: A possible early key event in development of intestinal damage induced by chemotherapy. Dig Dis Sci 2001;46:257-261.
20. Prada Pardal JL, Lopez Miranda J, Torres Gomez A, Gomez Garcia P, Blanco Cerrada J, Trujillo Santos J, Jansen Chaparro S, Lopez Segura F, Perez Jimenez F: Efecto de la cicloporina subre los nivelos plasmaticos de acido urico en pacientes transplantados de medula osea. An Med Interna 1994;11:533-536.
21. Noordzij TC, Leunissen KML, van Hooff JP: Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use. Transplantation 1991;52:64-67.
22. Chapman JR, Harding NGL, Griffith D: Reversibility of cyclosporine nephrotoxicity after three months' treatment. Lancet 1985;1:128-129.
23. Morichau-Beauchant M, Beau P, Druart F, Matuchansky C: Effects of prolonged, purine-free total parenteral and enteral nutrition on urate homeostasis in man. Am J Clin Nutr 1982;35:997-1002.
24. Batuman V, Dreisbach A, Maesaka JK, Rothkopf M, Ross E: Renal and electrolyte effects of total parenteral nutrition. J Parenter Enteral Nutr 1984;8:546-551.
25. Derus CL, Levinson DJ, Bowman B, Bengoa JM, Sitrin MD: Altered fractional excretion of uric acid during total parenteral nutrition. J Rheumatol 1987;14:978-981.
26. Sardesai VM: Molybdenum: An essential trace element. Nutr Clin Pract 1993;8:277-281.
27. Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J: Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001;357:587-591.
28. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, Arenas J, Negre E, Burke JT, Groth CG: Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002;2:436-442.
29. Baryalei M, Zenker D, Pieske B, Tondo K, Dalichau H, Aleksic I: Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2003;35:1539-1542.
30. Nguyen YK: Granulocyte colony stimulating factor. J Fla Med Assoc 1994;81:467-469.
31. Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B, Norfleet F, Chan KW, Champlin R, Korbling M: Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996;36:590-595.
32. Carreras E, Villamor N, Reverter JC, Sierra J, Granena A, Rozman C: Hypertriglyceridemia in bone marrow transplant recipients: Another side effect of cyclosporin A. Bone Marrow Transplant 1989;4:385-388.
33. Lopez-Miranda J, Perez-Jimenez F, Torres A, Espino-Montoro A, Gomez P, Hidalgo-Rojas L, Ordovas JM, Jimenez-Pereperez JA: Effect of cyclosporin on plasma lipoproteins in bone marrow transplantation patients. Clin Biochem 1992;25:379-386.
34. Socie G: Is syndrome 'X' another late complication of bone-marrow transplantation? Lancet 2000;356:957-958.
35. Gietema JA, Meinardi MT, van der Graaf WT, Sleijfer DT: Syndrome X in testicular-cancer survivors. Lancet 2001;357:228-229.
36. Luke DR, Beck JE, Vadiei K, Yousefpour M, LeMaistre CF, Yau JC: Longitudinal study of cyclosporine and lipids in patients undergoing bone marrow transplantation. J Clin Pharmacol 1990;30:163-169.
37. Lorini R, Cortona L, Scaramuzza A, De Stefano P, Locatelli F, Bonetti F, Severi F: Hyperinsulinemia in children and adolescents after bone marrow transplantation. Bone Marrow Transplant 1995;15: 873-877.
38. Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M: Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000;356: 993-997.
39. Mccann S, Apperley J, Cohen A, Kolb HJ, Socie G: Late effects of transplantation. Lancet 1999;354:778.
40. Deeg HJ, Socie G: Malignancies after hematopoietic stem cell transplantation: Many questions, some answers. Blood 1998;91:1833-1844.
41. Fernandez-Real JM, Grasa M, Casamitjana R, Ricart W: The insulin resistance syndrome and the binding capacity of cortisol binding globulin (CBG) in men and women. Clin Endocrinol (Oxf) 2000;52:93-99.
42. Shibutani Y, Ueo T, Takahashi S, Moriwaki Y, Yamamoto T: Effect of ACTH on renal excretion of purine bases in a patient with isolated ACTH deficiency. Clin Chim Acta 2000;294:185-192.
43. Kennedy DW, Abkowitz JL: Kinetics of central nervous system microglial and macrophage engraftment: Analysis using a transgenic bone marrow transplantation model. Blood 1997;90: 986-993.
44. Van Eck M, Zimmermann R, Groot PH, Zechner R, Van Berkel TJ: Role of macrophage-derived lipoprotein lipase in lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:E53-E62.
45. Herijgers N, de Winther MP, Van Eck M, Havekes LM, Hofker MH, Hoogerbrugge PM, Van Berkel TJ: Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knockout mice. J Lipid Res 2000;41:1402-1409.
46. Linton MF, Fazio S: Class A scavenger receptors, macrophages, and atherosclerosis. Curr Opin Lipidol 2001;12:489-495.
47. Hu P, Seeman TE, Harris TB, Reuben DB: Is serum uric acid level associated with all-cause mortality in high-functioning older persons: MacArthur studies of successful aging? J Am Geriatr Soc 2001;49:1679-1684.
48. Garcia-Lorda P, Bullo M, Vila R, del Mar Grasa M, Alemany M, Salas-Salvado J: Leptin concentrations do not correlate with fat mass nor with metabolic risk factors in morbidly obese females. Diabetes Nutr Metab 2001;14:329-336.
49. Bedir A, Topbas M, Tanyeri F, Alvur M, Arik N: Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J 2003;44:527-536.
50. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003;41:1287-1293.
51. Wojcik BE, Jinnah HA, Muller-Sieburg CE, Friedmann T: Bone marrow transplantation does not ameliorate the neurologic symptoms in mice deficient in hypoxanthine guanine phosphoribosyl transferase (HPRT). Metab Brain Dis 1999;14:57-65.
52. Nakata K, Gotoh H, Watanabe J, Uetake T, Komuro I, Yuasa K, Watanabe S, Ieki R, Sakamaki H, Akiyama H, Kudoh S, Naitoh M, Satoh H, Shimada K: Augmented proliferation of human alveolar macrophages after allogeneic bone marrow transplantation. Blood 1999;93:667-673.
53. Thiele J, Kvasnicka HM, Beelen DW, Wenzel P, Koepke ML, Leder LD, Schaefer UW: Macrophages and their subpopulations following allogenic bone marrow transplantation for chronic myeloid leukaemia. Virchows Arch 2000;437:160-166.
54. Endres W, Helmig M, Shin YS, Albert E, Wank R, Ibel H, Weiss M, Hadorn HB, Hass R: Bone marrow transplantation in Lesch-Nyhan disease. J Inherit Metab Dis 1991;14:270-271.
55. Nyhan WL, Parkman R, Page T, Gruber HE, Pyati J, Jolly D, Friedmann T: Bone marrow transplantation in Lesch-Nyhan disease. Adv Exp Med Biol 1986;195:167-170.
56. Nyhan WL, Page T, Gruber HE, Parkman R: Bone marrow transplantation in Lesch-Nyhan disease. Birth Defects Orig Artic Ser 1986;22:113-117.
57. Nuckols JD: Autopsy findings in umbilical cord blood transplant recipients. Am J Clin Pathol 1999;112:335-342.
58. Miller AD, Eckner RJ, Jolly DJ, Friedmann T, Verma IM: Expression of a retrovirus encoding human HPRT in mice. Science 1984;225:630-632.
59. Milewski EA: Discussions on human gene therapy. Recomb DNA Tech Bull 1986;9:88-130.
60. Wolff JA, Friedmann T: Approaches to gene therapy in disorders of purine metabolism. Rheum Dis Clin North Am 1988;14:459-477.